Qiagen Balance Sheet Health
Financial Health criteria checks 6/6
Qiagen has a total shareholder equity of $3.8B and total debt of $1.6B, which brings its debt-to-equity ratio to 42.2%. Its total assets and total liabilities are $6.1B and $2.3B respectively. Qiagen's EBIT is $445.2M making its interest coverage ratio -17.4. It has cash and short-term investments of $1.1B.
Key information
42.2%
Debt to equity ratio
US$1.61b
Debt
| Interest coverage ratio | -17.4x |
| Cash | US$1.06b |
| Equity | US$3.81b |
| Total liabilities | US$2.31b |
| Total assets | US$6.12b |
Recent financial health updates
Here's Why Qiagen (NYSE:QGEN) Can Manage Its Debt Responsibly
Mar 20
These 4 Measures Indicate That Qiagen (NYSE:QGEN) Is Using Debt Reasonably Well
Dec 08Qiagen (NYSE:QGEN) Seems To Use Debt Quite Sensibly
Sep 04Is Qiagen (NYSE:QGEN) Using Too Much Debt?
May 23Qiagen (NYSE:QGEN) Seems To Use Debt Quite Sensibly
Feb 15We Think Qiagen (NYSE:QGEN) Can Stay On Top Of Its Debt
Oct 31Recent updates
Here's Why Qiagen (NYSE:QGEN) Can Manage Its Debt Responsibly
Mar 20Calculating The Intrinsic Value Of Qiagen N.V. (NYSE:QGEN)
Feb 13Qiagen N.V.'s (NYSE:QGEN) Price Is Out Of Tune With Earnings
Jan 23These 4 Measures Indicate That Qiagen (NYSE:QGEN) Is Using Debt Reasonably Well
Dec 08An Intrinsic Calculation For Qiagen N.V. (NYSE:QGEN) Suggests It's 41% Undervalued
Oct 24Qiagen: No Upsides Slated In FY'23 In Core Business Lines, Reiterate Hold
Sep 09Qiagen (NYSE:QGEN) Seems To Use Debt Quite Sensibly
Sep 04Calculating The Fair Value Of Qiagen N.V. (NYSE:QGEN)
Jul 17Qiagen: Major Asset Growth Needed In Post-Covid World
Jun 22Is Qiagen (NYSE:QGEN) Using Too Much Debt?
May 23Calculating The Fair Value Of Qiagen N.V. (NYSE:QGEN)
Apr 18Qiagen (NYSE:QGEN) Seems To Use Debt Quite Sensibly
Feb 15Qiagen: Strong Q4, Derisked Portfolio, Fairly Valued
Feb 14Qiagen Non-GAAP EPS of $0.53, revenue of $498M, FY23 guidance initiated
Feb 07If EPS Growth Is Important To You, Qiagen (NYSE:QGEN) Presents An Opportunity
Jan 18Qiagen, Helix partner to advance NGS companion diagnostics in hereditary diseases
Jan 06A Look At The Fair Value Of Qiagen N.V. (NYSE:QGEN)
Jan 04Qiagen's test gets FDA nod for companion diagnostic to Mirati's cancer drug Krazati
Dec 13Qiagen Non-GAAP EPS of $0.53 beats by $0.08, revenue of $500M beats by $17.91M
Nov 07We Think Qiagen (NYSE:QGEN) Can Stay On Top Of Its Debt
Oct 31Qiagen stock down after BHF downgrades rating to Neutral
Oct 10Calculating The Fair Value Of Qiagen N.V. (NYSE:QGEN)
Oct 04Qiagen to develop companion diagnostic for Neuron23's Parkinson's disease drug candidate
Sep 14Does Qiagen (NYSE:QGEN) Deserve A Spot On Your Watchlist?
Aug 25Is Qiagen (NYSE:QGEN) Using Too Much Debt?
Jul 28Qiagen Fails To Justify Inclusion In Long-Biased, Balanced Macro Portfolio
Jul 15Is Qiagen N.V. (NYSE:QGEN) Trading At A 36% Discount?
Jun 29Does Qiagen (NYSE:QGEN) Deserve A Spot On Your Watchlist?
May 26Is Qiagen (NYSE:QGEN) A Risky Investment?
Apr 29Are Investors Undervaluing QIAGEN N.V. (NYSE:QGEN) By 31%?
Mar 30Financial Position Analysis
Short Term Liabilities: QGEN's short term assets ($2.1B) exceed its short term liabilities ($1.1B).
Long Term Liabilities: QGEN's short term assets ($2.1B) exceed its long term liabilities ($1.2B).
Debt to Equity History and Analysis
Debt Level: QGEN's net debt to equity ratio (14.5%) is considered satisfactory.
Reducing Debt: QGEN's debt to equity ratio has reduced from 83.2% to 42.2% over the past 5 years.
Debt Coverage: QGEN's debt is well covered by operating cash flow (28.6%).
Interest Coverage: QGEN earns more interest than it pays, so coverage of interest payments is not a concern.